Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT01679990

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Pluristem Ltd. (from the registry)
Registry
  • NCT NCT01679990
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Germany, Israel, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01679990. Randomized; double masking; primary purpose treatment. Start 2012-11-05 (registry gives no type); primary completion 2018-03-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
Condition
Peripheral Artery Disease
Intervention (Biological)
PLX-PAD Low dose
Intervention (Biological)
PLX-PAD high doses
Intervention (Biological)
Double Placebo
Intervention (Biological)
high dose +Placebo
Lead sponsor
Pluristem Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01679990
Content hash
ae88f02286b6bee6df90a43f21fcf02ea9e9c2719bb815e04e79c00df56d910d